- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00797082
Magnetic Resonance Diabetic Cardiac Stress Imaging (MRDiabetics)
Magnetic Resonance Diabetic Cardiac Stress Imaging : MRDIABETICS
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale:
The incidence of diabetes is rising constantly. According to the WHO projections, the population of diabetics will double by 2025. In France, the current population of diabetics is estimated at 2.5 millions persons. The cause of death in diabetics involves a cardiovascular condition in approximately 65-80% of the cases. The leading event is myocardial infarction. The prevalence of silent myocardial ischemia (SMI) in diabetics varies widely from 10 to 30%. The prognosis of SMI is closely dependent on the presence or not of angiographically significant coronary artery stenosis - CAS (patients with SMI and CAS>70% show 31% of major cardiac events at 41±24 months vs only 1.4% in patients with SMI and no CAS>70%). It seems therefore important to identify diabetic patients with SMI and CAS especially knowing that endovascular or surgical treatments are available and can potentially improve the prognosis of such patients.
Myocardial Perfusion Scintigraphy (MPS) is widely prescribed to detect coronary stenosis. It has a high sensitivity (90%) but an intermediate specificity (75%), providing a significant amount of false positive cases. Such false positive cases are usually followed with unnecessary coronary angiographies. Myocardial Perfusion Stress MRI (MRI) has been recently developed and shows promising preliminary results (equivalent sensitivity, higher specificity compared to MPS) for the identification of coronary artery stenosis. Few studies directly compare MRI and MPS in the general population, none in the diabetic population.
Principal objective: To evaluate and compare diagnostic performances of MRI and MPS for the diagnosis of coronary insufficiency in diabetic patients free of known coronary disease.
Secondary objective:
- Cost efficacy analysis for the diagnosis of coronary insufficiency in diabetic patients free of known coronary disease.
- Impact of clinical information on MRI and MPS diagnostic performances.
Design:. Prospective, monocentric study, where MRI and MPS will be assessed in a centralised manner by 2 independent blinded readers (2 readers for each technique) and compared to coronary angiography (Gold Standard, assessed by 2 independent blinded readers).
Patient selection: Patient with diabetes (type 1 or type 2), free of known coronary disease, addressed for MPS.
Inclusion period length: 24 months
Follow up period length: 2 days
Principal judgement criteria:
Coronary angiography: positive diagnosis of CAS if stenosis >50% on the left coronary artery (trunk) or stenosis >70% on the IVA (inter ventricular artery), LCx (circumflex artery) or RCA (right coronary artery) and branches.
MPS : positive diagnosis of CAS based on the following criteria : severity perfusion index, reversibility, contractility anomalies, signal attenuation due to patient morphology.
MRI : positive diagnosis of CAS based on an algorithm including the following criteria : first pass perfusion defect at stress, reversibility at rest, Myocardial Delayed Enhancement.
Number of necessary patients: 165
Expected results: An assessment of MRI performances compared to MPS for the diagnosis of coronary insufficiency in diabetic patients free of known coronary disease that will help improve diagnostic strategy.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75018
- Hopital Bichat
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
- Patient older than 18 years old
- Patient with health care coverage ( social security or universal health coverage - CMU)
- Patient who had a prior medical examination
- Diabetic patient (type 1 or type 2) with no known coronary artery disease, addressed for myocardial scintigraphy
- Patient who was informed of objectives and constraints of the study and having given his consent in writing
EXCLUSION CRITERIA:
- Pregnant and lactating women
- Patients with known coronary disease (myocardial infarction, unstable angina, history of coronary artery disease)
- Patient with contra-indication for MRI claustrophobia, metallic foreign body in the eye, pacemakers, mechanical heart valve laid before 1985 Patient with specific contra-indication to vasodilators
- Severe hypotension < 90 mmHg
- Hypersensitivity to adenosine or dipyridamole
- Bronchial asthma, chronic obstructive pulmonary disease with obvious bronchospasm. Severe and known pulmonary artery hypertension
- Atrioventricular 2nd or 3rd degree blocks, long QT syndrome
- Tight known carotid artery stenosis (70% NASCET criterion), with no possible vascular substitution
- Patient with contra-indication to cardiac stimulation
- Unstable hemodynamic state and / or unstable angina not stabilized by drug treatment and/or decompensated or severe heart failure
- Known comorbidities : pregnancy and lactation, tight aortic valve or mitral valve stenosis, severe left-right shunt, severe pericarditis or abundant pericardial effusion
- Contra-indication to coronary angiography
- Renal failure with creatinine clearance < 30 ml / min
- Hypersensitivity to contrast agents that resulted in a serious complication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
MRI = Myocardial Perfusion Stress and MPS = Myocardial Perfusion Scintigraphy
|
MRI = Myocardial Perfusion Stress
MPS = Myocardial Perfusion Scintigraphy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
positive diagnosis of coronary artery disease.
Time Frame: 2 days
|
2 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
cost efficacy analysis for the diagnosis of coronary insufficiency in diabetic patients free of known coronary disease
Time Frame: 26 months
|
26 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jean Michel SERFATY, PHU, Assistance Publique
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- P070149
- AOR07022 (Other Identifier: French Ministry)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Insufficiency
-
Assistance Publique - Hôpitaux de ParisVolcano CorporationCompletedCoronary Artery InsufficiencyFrance
-
Onassis Cardiac Surgery CentreCompletedRenal Insufficiency, Chronic | Angioplasty, Transluminal, Percutaneous Coronary | Coronary AngiographyGreece
-
Kathirvel SubramaniamPacira Pharmaceuticals, IncCompletedCoronary Artery Disease | Valve Regurgitation, Tricuspid | Coronary Artery Stenoses | Valve Regurgitation, MitralUnited States
-
Seoul National University Bundang HospitalCompletedChronic Renal Insufficiency | Coronary AngiographyKorea, Republic of
-
Deutsches Herzzentrum MuenchenCompletedRenal Insufficiency, Chronic | Coronary Arteriosclerosis | Angioplasty, Transluminal, Percutaneous CoronaryGermany
-
Centre of Postgraduate Medical EducationNot yet recruitingSmoking | Chronic Coronary Insufficiency
-
Avant ImmunotherapeuticsCompletedMyocardial Ischemia | Mitral Valve Insufficiency | Aortic Valve Insufficiency | Coronary ArteriosclerosisUnited States
-
Rigshospitalet, DenmarkTerminatedCoronary Artery Disease | Aortic Stenosis | Aortic Aneurysm | Mitral Insufficiency | Aortic InsufficiencyDenmark
-
Cardiac Research Institute BVCompletedCoronary Artery Disease | Chronic Coronary InsufficiencySpain
-
Astana Medical UniversityCompletedCoronary Artery Disease | Mitral Valve Insufficiency | Aortic Valve InsufficiencyKazakhstan
Clinical Trials on MRI
-
Cambridge University Hospitals NHS Foundation TrustRecruitingBreast CancerUnited Kingdom
-
Assistance Publique Hopitaux De MarseilleActive, not recruitingMultiple SclerosisFrance
-
Seoul National University Bundang HospitalBayerCompletedTraumaKorea, Republic of
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedOsteosarcoma | Ewing Sarcoma | Paget's DiseaseUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
University of ZurichBalgrist University HospitalNot yet recruiting
-
Bragee ClinicsNot yet recruitingChronic Fatigue Syndrome
-
Abbott Medical DevicesCompletedAdverse Effect of MRI on an Implanted Pacemaker Lead | Adverse Effect of MRI on an Implanted PacemakerUnited States, Netherlands, Australia, Belgium, Finland
-
Brighton and Sussex University Hospitals NHS TrustCompletedLacrimal Duct Obstruction | Lacrimal StenosisUnited Kingdom
-
Rennes University HospitalBayerTerminatedMultiple Sclerosis (MS) | Inflammatory DiseaseFrance